Affordability of Antiviral Therapy in Asia-Pacific Countries and Its Impact on Public Health Outcomes.
作者信息
Udompap Prowpanga, Tanwandee Tawesak, Gani Rino
机构信息
Department of Medicine University of Minnesota Minneapolis MN.
Division of Gastroenterology Department of Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand.
出版信息
Clin Liver Dis (Hoboken). 2021 Jan 13;16(6):249-253. doi: 10.1002/cld.977. eCollection 2020 Dec.
Abstract
摘要
相似文献
1
Affordability of Antiviral Therapy in Asia-Pacific Countries and Its Impact on Public Health Outcomes.亚太国家抗病毒治疗的可负担性及其对公共卫生结果的影响。
Clin Liver Dis (Hoboken). 2021 Jan 13;16(6):249-253. doi: 10.1002/cld.977. eCollection 2020 Dec.
2
Availability, Price, and Affordability of Selected Essential Medicines for Chronic Diseases in 11 Countries of the Asia Pacific Region: A Secondary Analysis.亚太地区11个国家慢性病部分基本药物的可及性、价格及可负担性：一项二次分析
Asia Pac J Public Health. 2017 May;29(4):268-277. doi: 10.1177/1010539517700472. Epub 2017 Apr 11.
3
Reimbursement policies in the Asia-Pacific for chronic hepatitis B.亚太地区慢性乙型肝炎的报销政策。
Hepatol Int. 2015 Jan;9(1):43-51. doi: 10.1007/s12072-014-9593-x. Epub 2014 Dec 11.
4
Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries.亚太国家慢性乙型肝炎治疗的共识成本效益模型。
Hepatol Int. 2014 Jul;8(3):382-94. doi: 10.1007/s12072-014-9549-1. Epub 2014 Jun 27.
5
Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea.亚太地区药品价格监管的药品政策改革：以澳大利亚、中国、印度、马来西亚、新西兰和韩国为例
Value Health Reg Issues. 2019 May;18:18-23. doi: 10.1016/j.vhri.2018.08.007. Epub 2018 Nov 7.
6
Potential for Zika virus introduction and transmission in resource-limited countries in Africa and the Asia-Pacific region: a modelling study.寨卡病毒在非洲和亚太地区资源有限国家的传入及传播可能性：一项建模研究
Lancet Infect Dis. 2016 Nov;16(11):1237-1245. doi: 10.1016/S1473-3099(16)30270-5. Epub 2016 Sep 1.
7
Third Asian and Pacific Conference perspectives on family planning, population, and development.第三届亚太地区计划生育、人口与发展会议观点
Asian Pac Popul Programme News. 1984;13(2):25-30.
8
Bariatric/Metabolic Surgery in the Asia-Pacific Region: APMBSS 2018 Survey.亚太地区的减重与代谢手术：APMBSS 2018 调查。
Obes Surg. 2019 Feb;29(2):534-541. doi: 10.1007/s11695-018-3539-7.
9
Challenge and response: HIV in Asia and the Pacific.挑战与应对：亚太地区的艾滋病毒
Med J Aust. 1996 Nov 4;165(9):489-93. doi: 10.5694/j.1326-5377.1997.tb123234.x.
10
Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?亚太国家慢性乙型肝炎的治疗：亚太共识声明是否得到遵循？
Antivir Ther. 2010;15(4):607-16. doi: 10.3851/IMP1561.
引用本文的文献
1
Assessing pricing and affordability of HBV treatment in Asia-Pacific region: a barrier to elimination.评估亚太地区乙肝治疗的定价与可负担性：消除乙肝的一个障碍。
Hepatol Int. 2025 Apr;19(2):349-357. doi: 10.1007/s12072-024-10744-9. Epub 2025 Feb 3.
2
Risk Factors for Development of Cirrhosis in Chronic Viral Hepatitis B Patients Who Had Persistent Viral Suppression With Antiviral Therapy.接受抗病毒治疗后病毒持续抑制的慢性乙型肝炎患者发生肝硬化的危险因素。
J Clin Exp Hepatol. 2024 Jul-Aug;14(4):101388. doi: 10.1016/j.jceh.2024.101388. Epub 2024 Feb 27.
3
Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B.基于肝硬化、年龄和肝脏硬度的模型预测亚洲慢性乙型肝炎患者的肝细胞癌
Cancers (Basel). 2021 Nov 9;13(22):5609. doi: 10.3390/cancers13225609.
4
Challenges in the discontinuation of chronic hepatitis B antiviral agents.慢性乙型肝炎抗病毒药物停药面临的挑战。
World J Hepatol. 2021 Sep 27;13(9):1042-1057. doi: 10.4254/wjh.v13.i9.1042.
本文引用的文献
1
Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017.消除作为重大公共卫生威胁的病毒性肝炎的全球进展：对世卫组织成员国2017年应对情况的分析
JHEP Rep. 2019 May 10;1(2):81-89. doi: 10.1016/j.jhepr.2019.04.002. eCollection 2019 Aug.
2
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals.全球消除乙肝病毒和丙肝病毒感染运动：国际病毒性肝炎消除会议及迈向2030年消除目标的核心发展指标
J Virus Erad. 2019 Jan 1;5(1):60-66. doi: 10.1016/S2055-6640(20)30281-8.
3
Strategies for access to affordable hepatitis C testing and treatment in Asia.亚洲获得负担得起的丙型肝炎检测和治疗的策略。
Curr Opin HIV AIDS. 2019 Jan;14(1):1-6. doi: 10.1097/COH.0000000000000514.
4
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.慢性乙型肝炎的预防、诊断和治疗最新进展：美国肝病研究学会2018年乙型肝炎指南
Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.
5
Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.使用印度可获得的通用直接作用抗病毒药物治疗丙型肝炎的成本效益。
PLoS One. 2017 May 17;12(5):e0176503. doi: 10.1371/journal.pone.0176503. eCollection 2017.
6
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.EASL 2017 临床实践指南：乙型肝炎病毒感染管理。
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
7
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.《亚太地区乙型肝炎管理临床实践指南：2015年更新版》
Hepatol Int. 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4. Epub 2015 Nov 13.
8
Impact of partial reimbursement on hepatitis B antiviral utilization and adherence.部分报销对乙肝抗病毒药物使用及依从性的影响。
World J Gastroenterol. 2015 Aug 28;21(32):9588-97. doi: 10.3748/wjg.v21.i32.9588.
9
A 2015 roadmap for the management of hepatitis C virus infections in Asia.《2015年亚洲丙型肝炎病毒感染管理路线图》
Korean J Intern Med. 2015 Jul;30(4):423-33. doi: 10.3904/kjim.2015.30.4.423. Epub 2015 Jun 29.
10
Reimbursement policies in the Asia-Pacific for chronic hepatitis B.亚太地区慢性乙型肝炎的报销政策。
Hepatol Int. 2015 Jan;9(1):43-51. doi: 10.1007/s12072-014-9593-x. Epub 2014 Dec 11.
Zotero 插件